U.K.-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) is making news, but not in a good way. Its operations in China were…
Successfully navigating the stock market requires patience and a long-term perspective. The key is sticking to a consistent plan and…
Beijing’s mayor called on AstraZeneca Plc to expand its research and development investment in the Chinese capital, signaling that a…
Astrazeneca (AZN) closed at $65.35 in the latest trading session, marking a +1.41% move from the prior day.…
DJ PRESSESPIEGEL/Unternehmen Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires. THYSSENKRUPP - Der Industriekonzern Thyssenkrupp hat eine…
AstraZeneca announces board refresh with new directors…
AstraZeneca names new non-executive directors…
Finding a company that can make you a millionaire from a modest investment is rare. However, they are out there…
Some stocks sizzle, then fizzle. Others, though, build long-lasting momentum thanks to strong underlying business fundamentals. Three Motley Fool contributors…
SAN FRANCISCO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- AstraZeneca PLC (NASDAQ: AZN) is facing a significant crisis in…
From AstraZeneca to Vodacom, keep an eye on these global stocks this year.…
The quantum computing industry has emerged as one of 2024s hottest investing themes, with leading players seeing their stocks surge…
The FDA bestows a Breakthrough Therapy designation to AstraZeneca and Daiichi Sankyos Dato-DXd for previously treated advanced EGFR-mutated NSCLC.…
Whether youre looking for a way to beat the benchmark S&P 500 index or you just want a steady flow…
5 December 2024
Imfinzi approved in the US as first and only immunotherapy
regimen for patients with limited-stage small cell lung cancer
Based on…
The FDA approves AZNs Imfinzi for treating patients with limited-stage small-cell lung cancer based on phase III ADRIATIC study data.…
BAMBERG (dpa-AFX) - Im Prozess gegen den Pharmakonzern Astrazeneca um einen möglichen Corona-Impfschaden hat eine Frau aus Oberfranken einen…
BAMBERG (dpa-AFX) - Im Prozess gegen den Pharmakonzern Astrazeneca um einen möglichen Corona-Impfschaden hat eine…
4 December 2024
AstraZeneca appoints Iskra Reic as Executive Vice President, International
AstraZeneca today announced the appointment of Iskra Reic as Executive…
FTSE 100 drops 14 points London stock market exodus worsens Rio Tinto faces activist pressure 2..49pm: Wall Street opens higher…
FTSE 100 drops 18 points London stock market exodus worsens Rio Tinto faces activist pressure 4.05pm: FTSE still on its…
FTSE 100 drops 30 points European markets higher, ahead of French no-confidence vote Rio Tinto faces activist pressure 10.04am: Festive petrol…
The FTSE 100 soared on Tuesday in a broad rally driven by London’s heavyweight stocks including Shell, AstraZeneca, and HSBC.…
Success in 2025 for the pharma sector will hinge on the success of key drug pipeline developments, according to JPMorgan’s latest…
Success in 2025 for the pharma sector will hinge on the success of key drug pipeline developments, according to JPMorgan’s latest…
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat Astrazeneca mit einem Kursziel von 14000 Pence auf "Overweight" belassen. Das…
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat Astrazeneca mit einem Kursziel von 14000 Pence auf "Overweight" belassen. Das…
2 December 2024 15:00 GMT
Transparency Directive
Voting rights and capital
The following notification is made in accordance with the UK Financial Conduct…
Todays Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), AstraZeneca PLC (AZN) and Arista…
…
Ground-floor opportunities in transformative technologies dont come along often. Were in a unique moment in which two revolutionary sectors --…
Bad Marienberg (www.aktiencheck.de) - Laut Reuters hat AstraZeneca (ISIN: GB0009895292, WKN: 886455, Ticker-Symbol: ZEG, London Stock Exchange-Symbol: AZN), ein führender…
China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance amid an ongoing probe into its…
Data from a late-stage study shows that treatment with a three-drug combo involving AZNs Truqap benefits patients with an aggressive…
…
25 November 2024
Truqap combination in PTEN-deficient metastatic hormone-sensitive
prostate cancer demonstrated statistically significant and clinically meaningful
improvement in radiographic progression-free survival
in CAPItello-281 Phase III trial
First…
Theres nothing wrong with keeping things simple. Consider, for example, how a recipe can be ruined by straying too far…
There are plenty of growth stocks trading at obscenely high valuations right now. Part of the reason for that is…
AstraZeneca Plc’s recent share-price rout has gone so far that the pharma stock has shaken off the last of its…
20 November 2024
SINGAPORE — The National University Health System (NUHS) and Sahlgrenska University Hospital have formed a strategic partnership with…
ZÜRICH (dpa-AFX Broker) - Die Schweizer Großbank UBS hat die Aktien von Astrazeneca nach ihrem Kursrutsch bei unverändertem Kursziel…
ZÜRICH (dpa-AFX Broker) - Die Schweizer Großbank UBS hat die Aktien von Astrazeneca nach ihrem…
ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Aktien von Astrazeneca nach ihrem Kursrutsch bei unverändertem Kursziel von…
Uppsala, Sweden, November 19, 2024. The potency drug developer Dicot Pharma, which recently initiated a phase 2a clinical trial and…
18 November 2024
Tagrisso recommended for approval in the EU by CHMP
for patients with unresectable EGFR-mutated lung cancer
Recommendation based on LAURA Phase III…
1. Trump anti-vax health appointment wipes £7bn from AstraZeneca and GSK President-elect Donald Trump announced the controversial appointment of Robert…
Almost £7 billion was wiped from the combined market values of GSK PLC and AstraZeneca PLC on Friday after Donald Trump unveiled his…
AstraZeneca just released some encouraging data about its weight loss drug candidates.…
…
Kulmbach (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von…